QIAGEN N.V. Annual Report 2001

More documents

Recommendations

Info

The Life Science Research Market 8 Like the millions of water droplets that make up a cloud, a human chromosome is made up of millions of nucleotides, the basic units of DNA. The separation, purification, and handling of DNA and RNA are crucial for decoding their genetic information, and fundamental to life science research. QIAGEN offers a broad range of products to researchers around the world for both nucleic acid isolation and nucleic acid analysis.
QIAGEN — Focusing the Power of Life Sciences The life science research market is the birthplace of new technologies and applications for drug development, molecular diagnostics, and gene therapy that form the biotech marketplace. As such, it is QIAGEN’s most strategically important market. Academic and industrial life science researchers are QIAGEN’s core customers — it is for their applications that most of our tools and technologies are initially developed and standardized. As their applications and techniques evolve for use in the more demanding commercial biotech market, QIAGEN’s experiences from the research markets demonstrate proven technological excellence. QIAGEN has a broad portfolio of core technologies to serve this important market. We offer technologies to purify and separate nucleic acids from a wide range of starting materials — from simple bacteria to complex plants, cells, tissues, and clinical samples — and to address the many and varied throughput and purity needs of our customers. This comprehensive range of core technologies provides the high-quality building blocks needed to develop specialized QIAGEN products to meet the demands of the diverse customers in the life science market. In 2001, QIAGEN launched 17 new products for the life science research market, some of which are already used in drug development and molecular diagnostic applications. These include new applications of our core technologies for nucleic acid purification and handling, as well as new technologies for downstream applications for purified nucleic acids and proteins which can benefit from a direct and seamless integration into our core products. QIAGEN introduced several new products for PCR, including products and kits for quantitative real-time PCR and RT-PCR analysis. These kits are the first in a line of new products that provide the accurate quantification of DNA and RNA essential for gene expression analysis. QIAGEN also expanded its market and technology leading product portfolio in protein expression, purification, and analysis. QIAGEN will continue to develop and introduce new products for life science research, to take full advantage of the growing opportunities and expand its strong position in this strategically important market. QIAGEN’s customer base in the research market. 9
Page 1 and 2: QIAGEN N.V. Annual Report 2001 QIAG
Page 3 and 4: Financial Highlights Financial High
Page 5 and 6: Report of the Supervisory Board Eri
Page 7 and 8: Letter from the Managing Board To O
Page 9: QIAGEN — Focusing the Power of Li
Page 13 and 14: — Cellomics QIAGEN — Focusing t
Page 15 and 16: QIAGEN — Focusing the Power of Li
Page 17 and 18: QIAGEN — Focusing the Power of Li
Page 19 and 20: SELECTED CONSOLIDATED FINANCIAL DAT
Page 21 and 22: RESULTS OF OPERATIONS The following
Page 23 and 24: Operon, and QIAGEN Sciences, Inc. (
Page 25 and 26: as a result, operating costs relate
Page 27 and 28: credit lines totaling $9.6 million
Page 29 and 30: $360,000, based on the year-end int
Page 31 and 32: QIAGEN N.V. AND SUBSIDIARIES CONSOL
Page 39 and 40: in affiliated companies that are 50
Page 41 and 42: n. Financial Instruments In the ord
Page 43 and 44: December 31, 2001 (January 1, 2001
Page 45 and 46: During 1997, the Company purchased
Page 47 and 48: On March 20, 1997, the Company sold
Page 49 and 50: As of December 31, 2001 and 2000, t
Page 51 and 52: Long-term debt consists of the foll
Page 53 and 54: The Company has elected to adopt SF
Page 55 and 56: 17. LICENSING AGREEMENTS The Compan
Page 57 and 58: Assets Germany United States Switze
Page 59 and 60: STATEMENTS OF INCOME FOR THE YEAR E
Page 61 and 62:
7. SHAREHOLDERS’ EQUITY The autho
Page 63 and 64:
OTHER INFORMATION 2. STATUTORY PROF
Page 65 and 66:
1977, Lecturer of Biophysical Chemi
Page 67 and 68:
Since June 27, 1996, the Common Sha
Page 69 and 70:
Corporate Headquarters QIAGEN N.V.
Page 71:
QIAGEN Investor Relations Dr. Solve
show all

QIAGEN N.V. Annual Report 2001

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?